LIPOPEPTIDE VACCINE WITH ACTIVITY AGAINST HUMAN CYTOMEGALOVIRUS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是测试两种候选巨细胞病毒疫苗，并确定这些疫苗的安全性和最佳剂量。巨细胞病毒感染虽然在健康人中是一个罕见的问题，但对于免疫力低下的人来说仍然是一个问题。在未出生的婴儿中，巨细胞病毒是导致智力迟钝的主要感染。在移植受者中，巨细胞病毒也会引起严重的肺部感染，并可能导致艾滋病患者失明。希望之城的研究人员发现，巨细胞病毒的一小部分，被称为“肽”，可以在对巨细胞病毒的正常人体免疫反应中被识别，这种肽已经在小鼠研究中被证明是活跃的。已经研制出一种疫苗，这种疫苗将巨细胞病毒肽附着在一种叫做“脂质”的化学物质上，这种化学物质有助于这种现在被称为“脂肽”的肽发挥疫苗的作用。此外，一种“辅助”肽也附着在脂肽疫苗上，以提高免疫力。有两种类型的疫苗（疫苗A和疫苗B）正在评估，它们具有相同的巨细胞病毒肽，但不同的辅助肽。还有两项疫苗接种试验：1)评估4种剂量水平的A和B疫苗在既往巨细胞病毒感染人群中的安全性和免疫效果；2)在从未感染过巨细胞病毒的志愿者中，评估A或B疫苗的安全性和免疫效果，根据安全性和免疫反应判断哪一种更好。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test two candidate CMV vaccines and to determine the safety and the optimal dose of these vaccines. CMV infection, although a rare problem in healthy people, continues to be a problem for persons with lowered immunity. In unborn babies, CMV is the leading infection linked to mental retardation. Also in transplant recipients CMV causes serious lung infection, and can cause blindness in AIDS patients. Investigators at City of Hope have discovered that a small piece of CMV, called a "peptide", can be recognized during the normal human immune response to CMV, and this peptide has already been shown to be active in mice studies. A vaccine has been made in which this CMV peptide is attached to a chemical, called a "lipid", which helps the peptide, now called a "lipopeptide", to work as a vaccine. In addition, a "helper" peptide is also attached to the lipopeptide vaccine to improve immunity. There are two types of vaccine (vaccine A and vaccine B) being evaluated, and these have the same CMV peptide but different helper peptides. There are also two vaccination trials: 1) Evaluation of safety and immune effect of 4 dose levels of vaccine A and B in persons who have previously had a CMV infection; and 2) Evaluation of safety and immune effect of either vaccine A or B, whichever is better based on safety and immune response, in volunteers who have never had previous CMV infection.